newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - TELEFLEX INC

Thanks, everybody, for joining us. I'm Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jeffries, and I'm really pleased to be joined by Teleflex Management, including Jason Wyman, the CEO, and John Darin, and also Larry Cush here in the room. So we'll have about 25 minutes for Q&A. Maybe I'll kick things off, Jason. Sure. Pleasure to host you. You've been in the seat for about five months, coming from a cardio background and into a company that has some big cardio aspirations. So I would love to get sort of your assessment in the initial five months. You know, what attracted you to Teleflex? And maybe talk about that specific opportunity, too, in cardio now with the Biotronic acquisition, complementing what we already had from the legacy vascular business. Yeah, sure. Sure. So look, looking at the opportunity before I started, I was interested and very intrigued by the portfolio transformation that was going on, the opportunity to kind of shrink and focus, and really with what we're going to be left with here at the Remain Co. when all that transformation is done is three focus divisions. and i thought that was a good platform from which to grow i like the combination with bringing in biotronic vi to the legacy teleflex business those portfolios looked work really well together i could see that from the outside coming from that space coming in now five months i've really spent a lot of time diving in trying to really better understand our products the therapies how the company works i've been to all of our sites you know many of them more than once talk to employees all over. And I'd say at the end of all of that, first and foremost, it just really reinforced my conviction of what we have here. We've got great products, market-leading positions in a lot of key categories, strong brands, and so a really good foundation from which to grow. We got great employees who are hungry for change and want to do things differently. The other thing I would say is it's really kind of colored where I think we need to go going forward. So really got three priorities. The first is really focused on foundational things. We've got a lot of stuff we're still finishing off. Obviously, we've got the divestitures and the ensuing work with that. We're going to have to finish the integration of Biotronic VI into Teleflex. From there, we have got some work on our operating model. We are doing some things to simplify our operating model, making some major changes to move to a global business unit, and then we're going to elevate our growth profile. Those are the three main priorities going forward. Those are probably three great things double click on so maybe we could start by just talking about the progress with the divestiture remind us of the timeline with the second one and then your goals for capital deployment along alongside that sure so with the divestitures as a reminder we had two different divestitors that that happened one was with our OEM business that closed already that was about three quarters of the proceeds and so that's done already we still have the the divestiture of the acute care and interventional urology business that's in process. So where we are specifically with that right now is that we had a second request from the FTC earlier this year. It just relates to a small product overlap with the buyer's portfolio. It's very defined and manageable. It's not a big issue. This is a buyer-driven process. So they've been working on a remedy, making great progress. We've supported them along the way. We're both actively driving to get that closed by the end of this calendar year. But as we talked about on our last call, you know, as we're working with the unknowns of a regulatory process, it could, you Know, go a little bit into 2027, but we're still super confident that it's going to close. It's just kind of working through the days that are left in the calendar. In terms of the use of those proceeds, we had committed to a billion dollars in share buybacks, $800 million in debt reduction already with the close of OEM. We've, and other things, we've finished $600 of the billion of the share buybacks, and we've paid down $700 million in debt. And so kind of the remaining $400 and $100 is what we would look to do as we do the final divestiture. And can you talk about your pro forma leverage and leverage goals and what this will mean now with the refreshed balance sheet to be able to do some? Yeah, I mean, we have, yeah. Yeah, right now, I think leverage is, you know, pretty low at 1.4. You know, I think we'll likely in the near term stay well under two is my thoughts. I mean, obviously, we have to get through the final integration of Biotronic, the disposition. So I think this year we don't see, you know, if the great asset comes our way that we have to buy, we'll probably likely do something. But I think right now we want to focus on getting the business stabilized, get the acquisition complete. So I would say likely you see us stay under two in the new year term. So, yeah, we committed to stay under three through all the turmoil, and we did that. I think, you know, we've had a lot of opportunity to pay down the debt a little bit ahead of schedule as well as we've done some buybacks ahead as well. So that's been incrementally useful, too. Great. Maybe we'll talk a little about the Biotronic integration. Sure. You talked about a few things that are happening, need to happen for that to work through and kind of get back on track. Can you talk about the progress through order to cash, hiring folks, and sort of getting the distributors, distributor transitions? Yeah, so in my first earnings call, we kind of brought this up where we were seeing some slowness or it was going, the integration was going slower than we expected. So it's really those three things that we isolated some of the challenges to. So if I kind of break them down. So on the order-to-cash side, you know, we, at this point, we've transitioned about 90% of the legacy Biotronic customers onto Teleflex ordering systems. So when you do that, that type of change, no matter how well the actual systems part of it goes, there can be some customer disruption. It can be confused no matter, no mater how much training you do, et cetera. And so we experienced some of that disruption as we went through that, particularly in Q2. To give you an example, in Europe, where a huge portion of that biotronic business was, we had about 7% of orders that were just going to the wrong place and to kind of never land. We had to track down and try to – so that's a huge number. You don't want it to happen. As we worked through Q3 and got kind of tied up those loose ends, we had that far under 1%. So we got that under control. So we feel pretty good about that. We've got about 10% of customers left across the globe that we have to transition. But, you know, we feel good about kind of the staging that will happen there. Second area was distributors and the transition with distributors. So we inherited a sizable book of indirect business from Biotronic BI. you know obviously when that first comes in you're they're under you're inheriting the other companies actual distributors and their contracts so when that happens you don't necessarily have full visibility to how they are going to order nor do they have a huge incentive to work really collaboratively with you if they're not going to be the long-term distributor so for those first couple of quarters before we had transitioned things over to teleflex it became a challenge for us and so at this point though as we finished q3 87 percent of the indirect business now is running through either our um our distributors legacy teleflex distribute distributors and or we've converted them to teleflax contracts so now at thispoint we have that clear line of sight to what's going on with the distributors, their ordering patterns, and are working much more collaboratively with them. So we kind of understand where that's going. So we've turned that quarter of where that distributor business had been coming down since the acquisition, and now I feel strongly that that will be on the upswing now. The last piece was just really on the Salesforce transition, and as we brought the Salesforce's together, and we had a lot of open heads, particularly in the United States, And this was really that, you know, as you bring these two very complementary portfolios together, you had people on both sides that were used to selling the opposite type of product, and a lot of them were going to be really great at selling the whole bag, and we found a lotof them were only going tobe great at sellin' their old portion of the bag, and that, frankly, was unacceptable, and we needed to find new people. So we had a lot oopen spots, but by the end of Q3, those had decreased by almost two-thirds. And I would say probably even more important to me is that the quality of people that we're getting in is excellent now. And I think I mentioned this on our Q3 call that we are starting to get cold calls from some of the best people in the industry, even when we don't have spots open. And I Think that says a lot to what we have in our bag, what people see in leadership, and where we are going and the potential. One interesting comment you made before was looking at it from the outside and coming from Medtronic. You said these things coming together was kind of an interesting play. And so I'd love for you to just explain sort of what Teleflex had in the legacy business and what Biotronic brings to that and where there's a lot of synergy having that bag together. Yes, sure. So in the interventional procedures, in the interventional space, the first part of a procedure is gaining access and getting to the lesions to be treated. And particularly as patients and lesions to be treated have gotten more complex over time, there's a lot of specialized tools that are needed to actually access and do the treatment. So Legacy Teleflex was excellent at that. And they're very well known. They've created some of the categories that are product categories that are used by almost all physicians around the world. So very, very good at that, but then Teleflax did not actually have the treatment devices. And that's where Biotronic VI came in, where they actually had the treatment devices. So same procedure, it's increasing your share of wallet, same rep could be in that procedure and sell that whole continuum of devices. And so that is how those two pieces come together. I would say the one thing I would note with the treatment device is from Biotonic VI is when I was at Medtronic, honestly what we used to always say is we're really glad that Biotronics sales and marketing isn't better because their products are really good. And so, you know, that was one of the things that excited me is if we put these portfolios together, we know we have really great products across the board. What can we do with that when you have a complete portfolio and you put the right leadership behind it? We just brought in new leadership in the interventional business. And what can we really drive? And I'm excited to see what we can do. Yeah. And maybe talk about the talent aspect, too. It's interesting that you're getting these cold calls and a lot of good talent. And, of course, you're a cardio guy, so you have lot of relationships, I'm sure, to be able to leverage that, too, Our old friend Sean Salmon is on the board, so I know he knows a lot of cardio folks. So maybe just speak to what do you think is really attracting the talent? How are you using your networks to leverage and get talent into the organization? Yeah, I think, you know, first and foremost, I think when people are looking at an organization, they want to see a prospect for the future. And in the interventional business, there is this really nice complete bag. And I think one of the challenges Teleflex Interventional has or has had since the combination with VI is that a lot of people just didn't know that it had come together and what that portfolio looked like. So this is an awareness issue that we've been addressing, not just with customers, but also with potential candidates. So a lot OF the people I've talked to as people have come forward were kind of even shocked to understand all of the pieces in the portfolio. And then they get excited, you know, particularly if they're in the selling organization, they get excited about being able to sell those types of aspects in the bag. And I think just the other part, again, is do they have somebody they can get behind and that they feel like they'd be excited to work for? And particularly Jason Fontana, who we brought in to run that business, who came in in September, he has a really strong following of people that have worked for him in the medical device industry for 20 plus years and i honestly i think you'd be hard-pressed to find anyone that has better customer relationships than him i mean he is as steeped in the in in customer relationships as anybody so i guess putting all that together you know having gotten through a lot of the distributor issues the order to cash now hiring maybe talk a little bit about the outlook for that business and what kind of improvements and growth could we see in the coming quarters and ultimately what's your goal for that division for growth yeah i think right now our goal um is to see continuous improvement um you know every quarter and so we saw some some improvement in this last quarter but my expectation is is we continue to do that and first and foremost we want to set ourselves up for a solid 2027 then we want To be able to get it back to market growth and then set it up for for long-term success and um and i think again we're in a really great position here because as we just talked about we have these great products we have the right leadership in place and then you can then look at what are our vectors for growth within that business as we get it was we get that foundation shored up we have a lot of room for share gain particularly in those treatment devices you combine that with our portfolio pull through the treatment devices second area second vector of growth within interventional huge opportunity internationally, more so than a lot of other med tech segments. A huge percentage of PCIs or coronary treatments, interventional treatments, are done outside the U.S., so there's a lot of room for us. We're underweight internationally, so there is a lot, or outside of Europe and the U S, so, there's lot of room there. And then the third growth factor is really going to be new product introductions. We've got a rich pipeline of things coming out, big and small, and we're excited about that. Yeah, maybe one of the bigger ones we could touch on is Freesolve. So there's been some buzz around the idea of leaving nothing behind. This is a stent that resorbs after some time. Early data looks pretty good. So maybe you could talk a little bit more about it, the data released next year, and when that could become a commercial reality. Yeah, sure. So maybe taking a step back so that everybody understands what Freeslove is. So when you're treating a coronary artery, you have a blockage. And stents were invented originally because you used to clear it with a balloon, but then a huge percentage of the time it would just recoil back. So you need some scaffolding there to keep that blockage open. But then you only really need it there for about 6 to 12 months, and then the vessel remodels. And so if it was gone at that point, it would be totally fine. So for decades, the dream has been to have a stent or a scaffold go in and then disappear when you don't need it anymore. So we've seen nothing left behind, drug-coated balloons come out, and frankly that's just because absorbable scaffolds haven't worked yet. You still have those acute closure issues. If you look at those trials and look at the amount of times there's a crossover and you end up having to put in a permanent stent, it's about 10% of the time. So the world would still prefer to have an absorbable scaffold in the ideal state. So that has been tried many times. For 30 years, people have tried. And fundamentally, the challenge in this is that great idea, but it's been difficult technically. And almost every other attempt has been with these absorbable scaffolds that have been made out of plastic. So when you have a plastic scaffold, it doesn't have the mechanical properties of a metal. It doesn't Have the radial strength. It's hard to deliver. It's hard to implant, and they take two to three years to absorb. And so fundamentally, that resulted in poor clinical results. With Freesolve, what we have is an absorbable metal. So we are unique in that standpoint. It's taken over 20 years to develop, so it's a huge technological leap. When you put this in front of a physician, they will look at it and say, this is completely different than what Abbott was trying to do with Absorb. It is much more like if you had a standard stent, an absorb, and freesolve. Freesolve looks like the standard stents, not like an absorb. It has the mechanical properties of a metal stent. It delivers great. It implants like a normal stent as the radial strength of a normal stent so we've had these, as you said, intriguing and really positive early results in our single arm clinical trial but we have to see how this performs versus a drug-eluting stent in a randomized fashion so we'll get our first readout of that in about a year. So if we're sitting in these chairs next year, we can talk about that. We'll have the data at that point on the first 2,000-patient randomized trial. And then we have a second pivotal randomized trial that is ongoing in the U.S. Great. And I want to talk a little bit more about your innovation. One of my jokes is I think Teleflex is known for really cool product names. So you've got RePlaz, EasyPlaZ coming out. I also like the TrapLiner catheter is a good one. Yeah. But let's talk about EasyPLAZ and the opportunity there. It's been kind of a long time coming. Very unique product, so I'd love for you to expand on what that is, why it's so unique, and maybe talk about this initial $200 million opportunity that you've identified. Yeah, sure. So EasyPlaz is freeze-dried plasma, and I would say, to be honest, coming into Teleflux, I did not know a lot about it, and this is one of the more exciting things for me as I've come in to learn about and really dive in and understand. And one thing of note is that people have been trying to develop freeze-dried plasma for literally almost 100 years. And there have been other attempts at it. There have been things that have been out there that ended up not working. And so it's a very, very challenging technical problem. So really proud of our team to get this through and now become the first FDA-approved device for freeze-drived plasma. So what you have is this device that can be stored or product that is stored at room temperature. You add saline to it. It can be reconstituted literally in a couple of minutes, and we do have a 12-month shelf life on it now. It's also in a plastic bag, which may sound kind of like not exciting, but actually that's like one of the wonders of the development is that other people developing freeze-dried plasma, They've only been able to freeze-dry it into a glass container, which, as you can imagine, in trauma situations and military situations, you don't want to be carrying around a glass-container plasma. It's better to have it in a flexible bag. So we've had tremendous feedback from all sorts of potential customers and excitement around that. As you said, we recently have said that in the U.S. we think that the market opportunity is at least $200 million in the long term. This is a combination of government military applications as well as civilian applications. It's a market development play. It will take time for this to play out. We see our first focus in the vast majority of our current capacity is probably going to go to that military government use, and that's where we've been focusing our time in the short term, as we're also starting to parallel past some early efforts with the early adopters in the civilian segment. Great. Maybe with the few minutes we have left, I want to talk a little bit about numbers. I know you're not going to guide on 27 today, but maybe let's talk about some of the moving parts because we have still to close the second deal, so that's going to impact the timing of capital deployment, certainly. But you have talked about this underlying margin sort of pro forma of about 23% with the ability to build from there. What are the other puts and takes that people should think about for 2027? Yeah, so why don't I just start at a high level, and then I can – Sure. You're welcome, since you've been really quiet. We'll let you take it. So, yeah, so we have talked about that we would expect, you know, as we head into 2027, a meaningful improvement in our financials, and I would say that it also should be much more representative of what we think the company will be like going forward. So we will have expanded margins, and we would say within that first 12 months of closing that last divestiture, we would expect that to be around 23 percent from an operating margins standpoint. Our interest expense will be lower. We'll have lower share count. So we'll see this meaningful step up in EPS over time. So I think that that, in a nutshell, at a high level, you know, we're encouraged and excited about 2027. And, you know, there's a lot of things that I would say we should be looking for as we enter into 2027. When do we exactly close that last divestiture? And then from an opportunity standpoint, obviously, we're looking for continued improvement in the interventional business, like we talked about, that continuous improvement. And EasyPlaz will be a contributor next year. So all of those things are moving in our direction. I don't know if you have any. I think you got most of it there. I mean, the 23% expansion is really the, you know, the TSAs, MSAs, in addition to cost-out programs. And as some of those TSA's and MSAs roll off, the cost-outs programs increase and take up that slack. And keep in mind, I mean that to us is the baseline as the business has an opportunity to improve when you get some leverage in the P&L. You know, I would hope to see that margin continue to increase. And maybe just talk about the level of confidence that you have in the cost out programs basically matching the stranded cost. Yeah, listen, you're never going to find yourself with the perfect line, right? I mean, it's probably going to be a little lumpy. You know, we've had a lot of success. I'll be honest with you, we're going to have a lot more people We've had, excuse me, in 2026 not just identifying the additional cost out that we need to identify, but also getting to some of the programs a little earlier than we expected. So, you know, there'll be a bit of – I'll have a little bit of both going on for a while, and then, you knows, sometimes there'll some lumpiness. But as we talked about, when we look at the full 12 months, we kind of see that 23%. So there will be some lumpiness to that, but it will be overall consistent for like an annual basis. And then we have a lot of confidence in the ability to kind of cost out there. And frankly, you know, over the years as we've done manufacturing moves, other restructuring programs, it's something we've actually been pretty good at and we've been pretty consistent in delivering. And you've also said generally you expect to be able to expand margins beyond that in the future without giving specific goals yet. But maybe you could talk about sort of the main sources of that margin expansion in 28 and beyond. I would think growth and growth in cardio is going to be a big one. But what are the other sources of margin expansion, and what kind of expansion can we expect? Yeah, I mean, listen, I think when we talked about the separation and the strategic goals, you know, we talked About mid-60s for gross margin, then tariffs came in, and they ate up a little bit of that, right? You know, so that's, you Know, maybe 300 basis points ate up at gross margin. So we kind of see ourselves in that kind of low 60%. And, you know, it will bobble in particular quarters. So we have some products that are much greater gross margin than the average and some that are, frankly, less, right? And so depending on the outperformance, that mix will change quarter over quarter. But I kind of See the business in that similar margin profile, if you will. The opportunity as you grow, though, you will be on the other fixed costs, and that will help the margin improve as well. So as the top line improves, even if the gross margin stays the same, we should help leverage that margin even further. You know, the original, the first cut really is that cost out, right, as we take that cost out in the next two years. That's where your big expansion comes from initially, and then it's P&L leverage, as I said. Maybe one of my favorite questions is just what's your tariff strategy? You know I've been in the backyard looking for your plane to go into Mar-a-Lago. I haven't seen it yet. We don't have a plane anymore. That was part of our cost estimate. Yeah, yeah, we did take out the plane. So, you know, as a, you Know, listen, it's hard to know what the administration may consider doing next. You know, these 232 investigations, you Now, we're thinking about $30-ish million for next year. You know the big strategies we have, you We've taken a lot out of the USMCA because we have a lot of manufacturing in Mexico. So we've done most of what we can do there, honestly. There are still a fair amount of components that need to come from other places. And so, unfortunately, I think we've kind of hit where we expect to be from USMCA. Are we going to move manufacturing back to the United States? Not likely. So deals like BD, I don't think you're going to see that from Teleflex. Frankly, the leverage we still get out of operating in a low-cost region is significant, even with the tariff. Great. Well, guys, thanks so much. Thanks for your time. And thanks, everybody, for your interest in Teleflex.

Company
TELEFLEX INC
Keywords
TELEFLEX INC